BRPI0811198B8 - fosfatase alcalina direcionada a osso, kits e métodos de seu uso - Google Patents

fosfatase alcalina direcionada a osso, kits e métodos de seu uso

Info

Publication number
BRPI0811198B8
BRPI0811198B8 BRPI0811198A BRPI0811198A BRPI0811198B8 BR PI0811198 B8 BRPI0811198 B8 BR PI0811198B8 BR PI0811198 A BRPI0811198 A BR PI0811198A BR PI0811198 A BRPI0811198 A BR PI0811198A BR PI0811198 B8 BRPI0811198 B8 BR PI0811198B8
Authority
BR
Brazil
Prior art keywords
amino acid
alkaline phosphatase
kits
bone
methods
Prior art date
Application number
BRPI0811198A
Other languages
English (en)
Portuguese (pt)
Inventor
Boileau Guy
Landy Hal
Lemire Isabelle
Crine Philippe
Leonard Pierre
Heft Robert
P Loisel Thomas
Original Assignee
Alexion Holding B V
Alexion Pharma Gmbh
Alexion Pharma Holding Unlimited Company
Alexion Pharma Int Sarl
Alexion Pharma Inc
Enobia Canada Lp
Enobia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Holding B V, Alexion Pharma Gmbh, Alexion Pharma Holding Unlimited Company, Alexion Pharma Int Sarl, Alexion Pharma Inc, Enobia Canada Lp, Enobia Pharma Inc filed Critical Alexion Holding B V
Priority to BR122019000505-2A priority Critical patent/BR122019000505B1/pt
Publication of BRPI0811198A2 publication Critical patent/BRPI0811198A2/pt
Publication of BRPI0811198A8 publication Critical patent/BRPI0811198A8/pt
Publication of BRPI0811198B1 publication Critical patent/BRPI0811198B1/pt
Publication of BRPI0811198B8 publication Critical patent/BRPI0811198B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
BRPI0811198A 2007-05-11 2008-05-12 fosfatase alcalina direcionada a osso, kits e métodos de seu uso BRPI0811198B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019000505-2A BR122019000505B1 (pt) 2007-05-11 2008-05-12 Fosfatase alcalina direcionada ao osso, kits e métodos de seu uso

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
US60/917,589 2007-05-11
PCT/CA2008/000923 WO2008138131A1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Publications (4)

Publication Number Publication Date
BRPI0811198A2 BRPI0811198A2 (pt) 2014-10-21
BRPI0811198A8 BRPI0811198A8 (pt) 2018-08-14
BRPI0811198B1 BRPI0811198B1 (pt) 2021-03-09
BRPI0811198B8 true BRPI0811198B8 (pt) 2021-05-25

Family

ID=40001639

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0811198A BRPI0811198B8 (pt) 2007-05-11 2008-05-12 fosfatase alcalina direcionada a osso, kits e métodos de seu uso
BR122019000505-2A BR122019000505B1 (pt) 2007-05-11 2008-05-12 Fosfatase alcalina direcionada ao osso, kits e métodos de seu uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019000505-2A BR122019000505B1 (pt) 2007-05-11 2008-05-12 Fosfatase alcalina direcionada ao osso, kits e métodos de seu uso

Country Status (25)

Country Link
US (1) US20100297119A1 (cg-RX-API-DMAC7.html)
EP (3) EP2158319B1 (cg-RX-API-DMAC7.html)
JP (1) JP5732603B2 (cg-RX-API-DMAC7.html)
AT (1) ATE536413T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008250945B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0811198B8 (cg-RX-API-DMAC7.html)
CA (1) CA2687001C (cg-RX-API-DMAC7.html)
CY (1) CY2016005I2 (cg-RX-API-DMAC7.html)
DE (1) DE202008018131U1 (cg-RX-API-DMAC7.html)
DK (3) DK2368999T3 (cg-RX-API-DMAC7.html)
ES (3) ES2619332T3 (cg-RX-API-DMAC7.html)
FR (1) FR16C0007I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20140416T1 (cg-RX-API-DMAC7.html)
HU (2) HUE031655T2 (cg-RX-API-DMAC7.html)
IL (1) IL202057A0 (cg-RX-API-DMAC7.html)
LT (1) LTC2368999I2 (cg-RX-API-DMAC7.html)
LU (1) LU92976I2 (cg-RX-API-DMAC7.html)
ME (1) ME01828B (cg-RX-API-DMAC7.html)
NL (1) NL300798I2 (cg-RX-API-DMAC7.html)
NO (1) NO2016002I2 (cg-RX-API-DMAC7.html)
PL (3) PL2662448T3 (cg-RX-API-DMAC7.html)
PT (3) PT2368999E (cg-RX-API-DMAC7.html)
RS (1) RS53302B (cg-RX-API-DMAC7.html)
SI (2) SI2662448T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008138131A1 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3404102B1 (en) 2004-04-21 2021-08-11 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
KR101580937B1 (ko) 2007-06-01 2015-12-31 유니버시티 오브 매릴랜드, 발티모어 면역글로불린 불변영역 Ｆｃ 수용체 결합제
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
CN103153344A (zh) 2010-04-30 2013-06-12 阿莱克森国际制药有限公司 用于治疗基质矿化障碍的方法、组合物、和试剂盒
DK2598533T3 (en) 2010-07-28 2019-04-23 Gliknik Inc Fusion proteins of natural human protein fragments to create in an orderly fashion multimerized immunoglobulin FC compositions
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
CA2852874A1 (en) * 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JP2015527366A (ja) 2012-08-20 2015-09-17 グリックニック インコーポレイテッド 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子
CN106164262B (zh) * 2014-01-24 2020-08-07 安-法玛公司 嵌合型碱性磷酸酶样蛋白
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
EP3226891B1 (en) 2014-12-05 2025-06-25 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
FI3325011T6 (fi) 2015-07-24 2023-05-11 Ihmisen proteiinifragmenttien fuusioproteiineja järjestyksenmukaisesti multimerisoitujen, paremmin komplementtia sitovien immunoglobuliini-fc-koostumusten muodostamiseksi
HK1257341A1 (zh) * 2015-08-17 2019-10-18 Alexion Pharmaceuticals, Inc. 硷性磷酸酯的制造
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) * 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
WO2017173395A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
CN109152820A (zh) * 2016-04-01 2019-01-04 阿雷克森制药公司 用碱性磷酸酶治疗肌肉无力
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
ES2887573T3 (es) 2016-06-27 2021-12-23 Alexion Pharma Inc Métodos para el tratamiento de la hipofosfatasia en niños y adolescentes
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
JP7649624B2 (ja) * 2016-11-30 2025-03-21 パーデュー リサーチ ファウンデーション 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生
WO2018107079A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Manufacturing optimization of gl-2045, a multimerizing stradomer
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
WO2018164995A1 (en) * 2017-03-09 2018-09-13 Alexion Pharmaceuticals, Inc . Glycoprotein manufacturing process
CA3057502A1 (en) * 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
JP7511469B2 (ja) 2017-09-27 2024-07-05 イノザイム ファーマ， インコーポレイテッド 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
EP3773686B1 (en) 2018-03-20 2023-06-07 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
ES3032290T3 (en) 2018-03-20 2025-07-16 Theriva Biologics Inc Intestinal alkaline phosphatase formulations
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
CN110499285A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Alpl基因在制备预防和/或治疗低碱性磷酸酶症的产品中的应用
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CN113993541A (zh) 2019-05-06 2022-01-28 合成生物制品有限公司 基于碱性磷酸酶的肿瘤学治疗
AU2020398898A1 (en) 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
EP4084819A1 (en) 2020-01-03 2022-11-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Tnap locally administered for promoting periodontal health
CA3190513A1 (en) * 2020-09-03 2022-03-10 Jeffrey S. Bartlett Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
CN117042791A (zh) 2021-02-12 2023-11-10 阿雷克森制药公司 碱性磷酸酶多肽及其使用方法
WO2024050464A2 (en) * 2022-08-31 2024-03-07 University Of Utah Research Foundation Gja1-20k compositions and methods for mitigating ischemia-reperfusion injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
HU223733B1 (hu) 1993-10-25 2004-12-28 Canji, Inc. Rekombináns adenovírus vektor és eljárás alkalmazására
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ES2284545T3 (es) 1999-11-16 2007-11-16 Genzyme Corporation Vectores y transgenes con elementos reguladores para la administracion de genes del higado.
US6808905B2 (en) 2001-05-14 2004-10-26 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
EP3404102B1 (en) 2004-04-21 2021-08-11 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
WO2006002203A2 (en) 2004-06-23 2006-01-05 Genzyme Corporation Methods and compositions for the treatment of polycystic diseases
WO2006039480A2 (en) * 2004-09-29 2006-04-13 The Burnham Institute For Medical Research Tissue non-specific alkaline phosphate (tnap): a therapeutic target for arterial calcification
BRPI0515819A (pt) 2004-12-01 2008-08-05 Genzyme Corp métodos para o fornecimento direcionado de material genético ao fìgado

Also Published As

Publication number Publication date
SI2368999T1 (sl) 2014-07-31
DE202008018131U1 (de) 2011-12-30
LTPA2016004I1 (lt) 2016-02-25
IL202057A0 (en) 2011-08-01
CA2687001A1 (en) 2008-11-20
AU2008250945A2 (en) 2009-12-24
EP2158319B1 (en) 2011-12-07
NO2016002I1 (no) 2016-02-02
DK2662448T3 (en) 2017-03-20
BR122019000505A2 (pt) 2021-12-14
ES2471915T3 (es) 2014-06-27
CY2016005I1 (el) 2016-08-31
PL2158319T3 (pl) 2012-05-31
EP2368999B1 (en) 2014-03-12
HK1191372A1 (en) 2014-07-25
PT2158319E (pt) 2012-03-06
EP2158319A1 (en) 2010-03-03
DK2158319T3 (da) 2012-03-19
LTC2368999I2 (lt) 2017-09-25
NO2016002I2 (no) 2016-02-02
EP2368999A1 (en) 2011-09-28
HK1141047A1 (en) 2010-10-29
CY2016005I2 (el) 2016-08-31
LU92976I2 (en) 2016-04-11
BR122019000505B1 (pt) 2022-01-18
EP2158319A4 (en) 2010-07-21
WO2008138131A1 (en) 2008-11-20
HUS1600005I1 (hu) 2016-02-29
JP2010526543A (ja) 2010-08-05
NL300798I1 (cg-RX-API-DMAC7.html) 2016-03-16
AU2008250945A1 (en) 2008-11-20
PL2158319T4 (pl) 2016-04-29
US20100297119A1 (en) 2010-11-25
BRPI0811198B1 (pt) 2021-03-09
FR16C0007I1 (cg-RX-API-DMAC7.html) 2016-04-15
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
BRPI0811198A8 (pt) 2018-08-14
ES2619332T3 (es) 2017-06-26
PT2368999E (pt) 2014-05-26
WO2008138131A4 (en) 2008-12-31
PT2662448T (pt) 2017-03-29
RS53302B (sr) 2014-08-29
ES2380546T3 (es) 2012-05-16
ATE536413T1 (de) 2011-12-15
BRPI0811198A2 (pt) 2014-10-21
FR16C0007I2 (fr) 2017-01-27
EP2662448B1 (en) 2016-12-21
HRP20140416T1 (hr) 2014-06-20
HK1162589A1 (en) 2012-08-31
SI2662448T1 (sl) 2017-05-31
NL300798I2 (cg-RX-API-DMAC7.html) 2016-03-16
DK2368999T3 (da) 2014-05-26
PL2368999T3 (pl) 2014-08-29
CA2687001C (en) 2019-02-12
AU2008250945B2 (en) 2013-12-12
JP5732603B2 (ja) 2015-06-10
PL2662448T3 (pl) 2017-07-31
WO2008138131A9 (en) 2009-08-06
ME01828B (me) 2014-12-20

Similar Documents

Publication Publication Date Title
BRPI0811198B8 (pt) fosfatase alcalina direcionada a osso, kits e métodos de seu uso
GT201000037A (es) Depsipéptidos cíclicos
BRPI0411528A (pt) uso de isomalte como prebiótico
CL2016003014A1 (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi) (divisional sol. n°230-11).
TR200201887T2 (tr) Sulu elastomer kaplama bileşimi ve bununla kaplanmış cisimler.
BRPI0418513A (pt) prótese de ombro com base para fratura umeral
GT200900187A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos
CR10303A (es) "derivados de quinolina y su uso com pesticidas"
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
BRPI0907317A2 (pt) composição farmacêutica e método para fabricar uma composição farmacêutica tópica em gel, espuma e em spray
BR112023022041A2 (pt) Anticorpos anti-tslp modificados
PA8781701A1 (es) Derivados de 7-alquinil-1,8- naftiridonas, su preparaciones y su aplicacion en terapeutica
BR112023021867A2 (pt) Composições de anticorpo anti-tslp e seus usos
SV2003000995A (es) Nuevas arilsulfonamidas como agentes antivirales ref. lea35214-sv
AR064219A1 (es) Cuerpo moldeado que contiene titanio
UY30552A1 (es) Combinaciones farmacologiicas en base a derivados sustituidos de la n-(5-{2-[1,1-dimetil-propilamino]-1-hidroxi-metil}-2-hidroxi-fenil)-metansulfonamida y aplicaciones
BRPI0603813A (pt) máquina de lavar automática com movimento de lavar toroidal e toroidal inverso
BRPI0416708A (pt) derivados de aminoquinazolidinadiona antibacterianos
BR112022024992A2 (pt) Formulações prontas para o consumo
GT200500250A (es) Hexadecasacaridos biotinilados, su preparacion y su utilizacion
BR112021022665A2 (pt) 12-oxaspiro [5,5] undec-8-eno úteis em composições de fragrância
TR202104290U5 (tr) Bi̇r su geçi̇rmez çorap
TR200606750U (tr) Pratik ayak bağlantı aparatı.
TWD199035S (zh) 懸臂工作車主構件
BRMU8501826U (pt) disposição construtiva em argola para cortinas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ENOBIA CANADA LIMITED PARTNERSHIP (CA)

B25A Requested transfer of rights approved

Owner name: ALEXION PHARMA INTERNATIONAL SARL (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ALEXION PHARMA GMBH (CH)

B25A Requested transfer of rights approved

Owner name: ALEXION HOLDING B.V. (NL)

B25A Requested transfer of rights approved

Owner name: ALEXION PHARMA HOLDING UNLIMITED COMPANY (BM)

B25A Requested transfer of rights approved

Owner name: ALEXION PHARMACEUTICALS, INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/05/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF